XSAT:DBP B (Sweden)
Â
B
kr
0.13
+0.0070 (+5.58%)
Jul 17
Business Description
Double Bond Pharmaceutical International AB
ISIN : SE0007185525
Share Class Description:
XSAT:DBP B: BTotal Employee Number:
8Compare
Compare
Traded in other countries / regions
DBP B.Sweden IPO Date
2015-07-10Description
Double Bond Pharmaceutical International AB is a pharmaceutical company. The company develops and commercializes approaches for the treatment of cancers, infections, autoimmune diseases, and other life-threatening disorders.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.85 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 6.38 | |||||
Beneish M-Score | 18.27 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year FCF Growth Rate | 49.3 | |||||
3-Year Book Growth Rate | -24.4 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.64 | |||||
9-Day RSI | 53.89 | |||||
14-Day RSI | 53.43 | |||||
3-1 Month Momentum % | -14.53 | |||||
6-1 Month Momentum % | -5 | |||||
12-1 Month Momentum % | -7.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.83 | |||||
Quick Ratio | 0.83 | |||||
Cash Ratio | 0.43 | |||||
Days Sales Outstanding | 212.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -39.7 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 3256.93 | |||||
Operating Margin % | -1140.15 | |||||
Net Margin % | 366.42 | |||||
EBITDA Margin % | 523.36 | |||||
FCF Margin % | -3429.2 | |||||
OCF Margin % | -3429.2 | |||||
ROE % | 5.58 | |||||
ROA % | 3.57 | |||||
ROIC % | -9.79 | |||||
3-Year ROIIC % | 391.37 | |||||
ROC (Joel Greenblatt) % | 1523.68 | |||||
ROCE % | 6.43 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.95 | |||||
EV-to-EBIT | 49.15 | |||||
EV-to-EBITDA | 39.69 | |||||
EV-to-Revenue | 207.73 | |||||
EV-to-Forward-Revenue | 15.33 | |||||
EV-to-FCF | -6.06 | |||||
Price-to-GF-Value | 2.21 | |||||
Earnings Yield (Greenblatt) % | 2.03 | |||||
FCF Yield % | -15.91 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Double Bond Pharmaceutical International AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 0.137 | ||
| EPS (TTM) (kr) | -0.01 | ||
| Beta | 2.1947 | ||
| 3-Year Sharpe Ratio | 0.08 | ||
| 3-Year Sortino Ratio | 0.15 | ||
| Volatility % | 89.36 | ||
| 14-Day RSI | 53.43 | ||
| 14-Day ATR (kr) | 0.013612 | ||
| 20-Day SMA (kr) | 0.12645 | ||
| 12-1 Month Momentum % | -7.49 | ||
| 52-Week Range (kr) | 0.09 - 0.268 | ||
| Shares Outstanding (Mil) | 222.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Double Bond Pharmaceutical International AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Double Bond Pharmaceutical International AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 116 days | ||
| Second quarter earnings results for 2026 | 2026-08-27 | In 38 days | ||
| First quarter earnings results for 2026 | 2026-05-22 | 0.12 (-7.48%) | ||
| General meeting for 2026 | 2026-04-23 13:00 | 0.14 (+0.00%) | ||
| Annual report for 2025 | 2026-03-26 | 0.12 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 0.12 (+2.21%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 0.11 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-26 | 0.13 (-6.69%) | ||
| First quarter earnings results for 2025 | 2025-05-23 | 0.32 (-5.87%) | ||
| Annual report for 2024 | 2025-05-22 | 0.34 (+6.25%) |
Show
Entries
Double Bond Pharmaceutical International AB Frequently Asked Questions
What is Double Bond Pharmaceutical International AB(XSAT:DBP B)'s stock price today?
The current price of XSAT:DBP B is kr0.13. The 52 week high of XSAT:DBP B is kr0.27 and 52 week low is kr0.09.
When is next earnings date of Double Bond Pharmaceutical International AB(XSAT:DBP B)?
The next earnings date of Double Bond Pharmaceutical International AB(XSAT:DBP B) is 2026-08-27.
Does Double Bond Pharmaceutical International AB(XSAT:DBP B) pay dividends? If so, how much?
Double Bond Pharmaceutical International AB(XSAT:DBP B) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Double Bond Pharmaceutical International AB
No articles.